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Glycosylation changes are a feature of disease states. One clear example is cancer cells,
which commonly express glycans at atypical levels or with different structural attributes
than those found in normal cells. Epithelial–mesenchymal transition (EMT) was initially rec-
ognized as an important step for morphogenesis during embryonic development, and is
now shown to be one of the key steps promoting tumor metastasis. Cancer cells under-
going EMT are characterized by significant changes in glycosylation of the extracellular
matrix (ECM) components and cell-surface glycoconjugates. Current scientific methodol-
ogy enables all hallmarks of EMT to be monitored in vitro and this experimental model has
been extensively used in oncology research during the last 10 years. Several studies have
shown that cell-surface carbohydrates attached to proteins through the amino acids, ser-
ine, or threonine (O-glycans), are involved in tumor progression and metastasis, however,
the impact of O-glycans on EMT is poorly understood. Recent studies have demonstrated
that transforming growth factor-beta (TGF-β), a known EMT inducer, has the ability to pro-
mote the up-regulation of a site-specific O-glycosylation in the IIICS domain of human
oncofetal fibronectin, a major ECM component expressed by cancer cells and embryonic
tissues. Armed with the knowledge that cell-surface glycoconjugates play a major role in
the maintenance of cell homeostasis and that EMT is closely associated with glycosylation
changes, we may benefit from understanding how unusual glycans can govern the mole-
cular pathways associated with cancer progression. This review initially focuses on some
well-known changes found in O-glycans expressed by cancer cells, and then discusses
how these alterations may modulate the EMT process.
Keywords: epithelial–mesenchymal transition, extracellular matrix, cancer, metastasis, glycosylation, oncofetal
fibronectin, glycosyltransferases
THE APPLICATION OF GLYCOBIOLOGY IN CANCER RESEARCH
Cancer is a complex progressive disease that involves a series of
genetic–environmental interactions, which cannot occur without
the dysfunction of multiple systems, including DNA repair, apop-
tosis, and immune function. Epigenetic mechanisms responding
to numerous internal and external cues in a dynamic ongoing
exchange play a key role in mediating environmental influences
on gene expression and tumor development. The cancer causing
agents (carcinogens) can be present in the air, chemicals, food,
water, and even the sunlight people are exposed to. Since epithelial
cells line the respiratory and alimentary tracts, cover the skin, and
metabolize carcinogens, it is not surprising that over 90% of can-
cers arise from epithelia (1). The sequencing of the human genome
holds benefits for many fields, from molecular medicine to human
evolution. The Human Genome Project (HGP) has helped in the
understanding of human diseases, including the identification of
oncogenes and mutations linked to different forms of cancer (2).
However, one major lesson from HGP is that the absolute number
of genes encoded by the human genome is not the best parameter
for defining its biological complexity. Instead, the complex func-
tions associated with human health and disease are determined by
combinatorial expansion of genomic information in the form of
post-translational modifications (PTMs).
The quantitative and qualitative control of a vast number of
proteins in eukaryotes is maintained by PTMs, such as phospho-
rylation, ubiquitination, methylation, hydroxylation, proteolysis,
N-acetylation, and glycosylation (3, 4). These intricate events
require a multitude of specific enzymes that are tissue- and
species-specific. The subsequent changes modulate the folding,
physicochemical properties, conformation, stability, distribution,
immunogenicity, and activity of the proteins (4–6). There is an
increasing awareness of post-genome glycosylation as a poten-
tially important form of post-translational protein modification.
Glycosylated proteins have long been known to participate in a
plethora of biological processes. These include signal transduc-
tion, inflammation, viral entry, bacteria–host interactions, cell–cell
interactions, and morphogenesis, as well as the development and
progression of chronic diseases, such as cancer (7–9). It is well-
accepted that in cancer cells, the expression and/or activity of
glycosyltransferases is altered, yielding an “aberrant” glycopheno-
type when compared to their normal counterparts (9, 10). These
changes result in structural variations of glycans on glycopro-
teins and glycolipids, altering their interaction with carbohydrate-
binding proteins and modulating the role of the membrane glycan
in cell adhesion and signal transduction required for cell motil-
ity (11, 12). Furthermore, the aberrant glycosylation of proteins
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in cancer cells offers an interesting diagnostic perspective in dis-
tinguishing what is benign and what is malign (13, 14). Several
glycoproteins carrying atypical glycophenotypes have been used
as cancer glycobiomarkers (15). Examples include the carcinoem-
bryonic antigen (16), the prostate-specific antigen (17), and the
CA-125 antigen (18), used as markers for colorectal, prostate, and
ovarian cancers, respectively. The transformation of glycobiology
from a descriptive and phenomenological discipline, to one where
the regulatory principles are understood and predictably manipu-
lated has opened up new opportunities in the study of cancer and
the search for effective therapeutic modalities.
O-LINKED GLYCAN STRUCTURES AND THEIR CHANGES IN
CANCER CELLS
Glycosylation is a main class of PTMs. There are two basic types
of protein glycosylation: N-glycosylation and O-glycosylation.
These have significant differences in terms of their biosynthesis
and structure, as well as their location within the protein chain
(7). In N -linked glycans, the nitrogen atom in the side chain
of asparagine is attached to N -acetylglucosamine (GlcNAc). The
sequence can be Asn-X-Ser or Asn-X-Thr, where X is any kind
of amino acid except proline (19). In O-linked glycans, the oxy-
gen atom in the side chain of serine or threonine is attached
to N -acetylgalactosamine (GalNAc) (20). Furthermore, the gly-
copeptides Asn-GlcNAc or Ser/Thr-GalNAc may be extended by
numerous and specific glycosyltransferases (7).
It is well understood that bothN - andO-linked glycans mediate
essential processes in development (21), host–pathogen interac-
tions (22–24), immune cell recognition (25), and cancer develop-
ment and progression (9, 26). In the case of cancer, alterations
in both glycan types frequently modulate the invasive poten-
tial of tumor cells and their interactions with stromal partners,
including fibroblasts, leukocytes, platelets, and endothelial cells
(27). This discussion focuses on the significance of O-glycan
changes in cancer evolution. However, there are many interest-
ing reviews addressing how atypical N -glycans may govern the
cancer development and progression [see reviews in Ref. (28, 29)].
In O-linked glycans, the oligosaccharides display considerable
structural and antigenic diversity. The GalNAc α-Ser/Thr link-
age has been considered a hallmark of mucins, where it occurs
in clusters (30). This linkage has also been found in a wide
variety of other proteins, such as extracellular matrix (ECM)
components (31). The path of O-glycosylation is a key factor
in the biological activity of glycoproteins involved with the con-
trol of cell differentiation and with the regulation of cell growth
through apoptosis and proliferation (32). The addition of GalNAc
to Ser or Thr is mediated by glycosyltransferases, known as N -
acetylgalactosaminyltransferases (GalNAc-Ts) (33). Furthermore,
the glycopeptide GalNAc α-Ser/Thr may be extended with addi-
tional sugars, including galactose (Gal), GlcNAc, fucose (Fuc), or
sialic acid (Sia). There is no glycan extension in cancer cells car-
rying mutations in the COSMC gene, which encodes for core-1
β3-Gal-T-specific molecular chaperone. Here, the glycopeptide
GalNAc α-Ser/Thr, referred to as Tn-antigen, may be sialylated
by the action of specific α2-6 sialyltransferases (α2-6 STs), cre-
ating the tumor-associated antigen known as sialyl Tn-antigen
(34). In general, there are four common O-glycan core structures
in mammalian tissues (core-1⇒ core-4) that depend on the
arrangement of the added sugars (Figure 1).
The biosynthesis of core-1 and core-2 structures is entirely
dependent on core-1-synthase, a galactosyltransferase (Gal-T),
which converts the initial glycopeptide (GalNAcα1-Ser/Thr) to
Galβ1-3GalNAcα1-Ser/Thr (core-1 or T-antigen). Core-1 is then
converted to core-2 by β1-6 N -acetylglucosaminyltransferase
(C2GnT). There are three enzymes that can synthesize core-
2: C2GnT-1, -2, and -3. Core-2 O-glycan is a scaffold for
the subsequent production of lactosamine repeats (poly-N -
acetyllactosamine) on O-glycans. Poly-N -acetyllactosamine for-
mation is a crucial step for the terminal modification by Sia and
Fuc (31). The carbohydrates that contain Sia or Fuc perform
important roles in the various steps of tumor formation and tumor
progression (35, 36). Enhanced expression of certain Sia types or
their linkages is often correlated with the poor prognosis for many
human malignancies. Core-3 O-glycan is synthesized onto the ini-
tial core-1 by core-3 synthase (β3GnT-6), which adds β1-3-linked
GlcNAc to GalNAc at the reducing terminus. Core-4 O-glycan is
then synthesized by the addition of β1-6 GlcNAc to the core-3
acceptor by C2GnT-2 (Figure 1).
FIGURE 1 | Pathways of O-glycan biosynthesis. To begin synthesis of
core-2 and core-4 O-glycans, GalNAc is transferred to a serine or threonine
residue in a polypeptide by the GalNAc-T. GalNAc-Ser/Thr is then converted
by core-1 synthase to Galβ1-3GalNAc-Ser/Thr (core-1). Core-1 is converted
to core-2 by C2GnT-1, -2, and -3. β-1,4-galactosyltransferase IV (β1-4Gal-T
IV), together with β-1,3-N -acetylglucosaminyltransferase V (β1-3GlcNAc-T
V), synthesizes poly-N -acetyllactosamine on core-2 O-glycans. The number
of Galβ1-4GlcNAc disaccharide unit repeats varies depending on the carrier
molecules and cell types. GalNAc-Ser/Thr is also converted by β3GnT-6 to
core-3. Core-3 is then converted by C2GnT-2 to core-4. As discussed in the
main text, the accumulation of truncated versions of expressed
oligosaccharides (T-, Tn-, and sialyl Tn-antigens) occurs due to impaired
activity of glycosyltransferases involved in the elongation of O-linked glycan.
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Out of the many known types of biosynthetic reactions in
O-linked glycosylation pathways, only a few structural changes
have been frequently connected with tumor development and
progression (9, 11, 37–42). Most are either truncated versions
of normally expressed oligosaccharides (T-, Tn-, and sialyl Tn-
antigens) (Figure 1) or relatively unusual types of outer/terminal
oligosaccharide sequences, such as Lewis structures. Such struc-
tures arise from the up-regulation of some glycosyltransferases, the
down-regulation of competing glycosyltransferases, or the changes
in the elongation of the core oligosaccharide structures that create
favored acceptors for the capping glycosyltransferases (9, 43). It
is well-documented that these truncated antigens show increased
expression in tumor cells, which make them potential cancer bio-
markers (41), and candidates for the development of vaccines
with anti-tumor properties (44). However, little is known about
their participation in cancer progression, since few papers have
addressed the biological impact of these structures in activating
molecular pathways related to cancer cell invasion and metastasis.
It is well described that mucins provide protection on epithelial
surfaces, and exert control on cell signaling. Nevertheless, mucins
in cancer cells carrying aberrant O-glycophenotypes induce pro-
found tumor-promoting effects, partly mediated through interac-
tions with their glycan moieties (45). MUC1 is greatly glycosylated
in benign cells of the breast, prostate, ovary, and pancreas, and is
minimally expressed and limited to the apical side of the glands.
Transformation of these cells into malignant cells is associated with
the over-expression of MUC1, and dysregulation of O-glycans of
MUC1 (46). Previous studies showed that the binding of galectin-
3 to MUC1 bearing the oncofetal Thomsen–Friedenreich antigen
[Galβ1,3 GalNAc-α (TF)] increases the cancer cell adhesion to
the endothelium (47). In addition, recent reports demonstrated
that the VNTR sequence found in the extracellular domain of
MUC1 may carry altered O-glycophenotypes, which could be
responsible to modulate cancer cell invasion and migration (48).
Recently, Wang and colleagues (49) described the strong pro-
carcinogenic potential of the N -acetylgalactosaminyltransferase-
3 (GalNAc-T3) in advanced epithelial ovarian cancer (EOC).
The authors demonstrated that the knockdown of GalNAc-T3,
a possible GalNAc-T involved in oncofetal fibronectin (onfFN)
biosynthesis (50), promoted an increase of the cell adhesion mol-
ecules β-catenin and E-cadherin. These are normally suppressed
by MUC1 in aggressive cancer cells, thus supporting the role of
the GalNAc-T3/MUC1 axis in EOC invasion (49). Although sev-
eral papers have connected the altered expression of MUC1 to
epithelial–mesenchymal transition (EMT) (51–54), the impact of
atypical O-glycans carried by MUC1 on cancer cells undergoing
EMT is still unknown.
Another example is the sialomucin CD43, which is one of
the most prevalent O-glycosylated mucins expressed by leuko-
cytes. It was found to be expressed by human adenomas and
carcinomas, but not in normal epithelial cells (55). In addition,
Fu and colleagues (56) recently demonstrated that human lung
carcinoma cells became more sensitive to TNF-α-induced cell
death after CD43 knockdown. However, the impact of CD43 on
EMT is unrecognized. So far, the roles of O-linked glycans in
promoting tumor metastasis have been investigated by focusing
on selectin-mediated interactions between tumor cells and other
cells types (57–60). Sialyl Lewis antigens, which may be found
in core-2 O-glycans, bind to selectins expressed on endothelial
cells, favoring the extravasation of cancer cells into metastasis
target organs (61, 62). Recently (63, 64), intracellular glycopro-
teins modified by a single O-linked-beta-N -acetylglucosamine
(O-GlcNAc) have shown to modulate cell–cell adhesion and cell
motility. The involvement of these O-GlcNAcylated glycoproteins
on EMT process has been described (65).
Since altered glycoconjugates expressed by cancer cells are
typically detected during fetal development, they are known as
oncofetal antigens. These proteins are often measurable in the
blood and may be used for cancer diagnosis and to monitor the
effectiveness of cancer treatment. Examples include α-fetoprotein,
which is produced by hepatocellular carcinoma and some germ cell
tumors (66), the carcinoembryonic antigen, which is elevated in
people with colon cancer (67), and O-glycosylated onfFN, which
was discovered in 1985 by Matsuura and Hakomori (68).
O-GLYCOSYLATED ONCOFETAL FIBRONECTIN: A MAJOR
ECM COMPONENT EXPRESSED BY CANCER CELLS AND
EMBRYONIC TISSUES
Since the same cell behaviors and processes that are indispensable
for embryonic development are also essential for cancer progres-
sion (69), it is not surprising that in the last two decades, we have
seen that cancer biology and development biology “walk hand
in hand” (70, 71). The notion that the local microenvironment
plays an essential role in regulating cell behavior, a central theme
in classical embryology, has become increasingly accepted in the
cancer biology field (72–74). Previous studies have been dedicated
to determining how cellular components of the niche initiate and
promote cancer development (75). However, more recent progress
has also highlighted the importance of non-cellular components of
the niche, especially the ECM during cancer progression (76–79).
The ECM is a mixture of many different molecular components
that vary between organisms, tissues within one organism, and
sometimes with the developmental age. It is not a static struc-
ture, but is instead being constantly remodeled by the cells within
it and around it, by the opposing influences of ECM synthesis
and destruction by proteolytic enzymes. The ECM is composed of
three main classes of macromolecules: structural proteins (colla-
gen and elastin), specialized proteins (fibrillin, laminin, and FN),
and glycosaminoglycans. Amongst all of the ECM components
in vertebrates, FN has received considerable attention for its role
in cell–matrix interactions. This adhesive glycoprotein is critically
important in vertebrate development, since gene disruption stud-
ies demonstrated early embryonic lethality in mice without the FN
gene. Although FN has been studied for more than two decades,
this remarkably complex molecule is still the subject of exciting
discoveries. FN usually exists as a dimer, composed of two nearly
identical ~250 kDa subunits linked covalently together near their
C-termini by a pair of disulfide bonds. FN binds different ECM
components and mediates homotypic interactions (Figure 2A).
Until the mid-80s, two major types of FN were known: the plasma
(pFN) and cellular FN (cFN), which was found in the pericellu-
lar matrix or secreted in the culture medium of fibroblasts. In
1985, Matsuura and Hakomori developed a monoclonal anti-
body (mAb) termed FDC-6, which was initially reactive with
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FIGURE 2 |The modular structure of fibronectin and its binding domains.
FN consists of type I, type II, and type III repeats. Sets of repeats constitute
binding domains for fibrin, FN, syndecan, collagen, and heparin, as indicated.
SS indicates the C-terminal cysteines that form the dimer. The EDB and EDA
domains that are produced by alternative splicing are indicated (A). Between
type I and type III repeats there is another alternatively spliced segment,
which is termed IIICS or variable region. During the alternative splicing, five
different IIICS variants may be generated (V0, V64, V89, V95, and V120).
Excluding V0, all others variants may hold the hexapeptide (VTHPGY) required
to create the O-glycosylated onfFN, which is produced from the addition of a
GalNAc unit at the Thr residue of the hexapeptide (VTHPGY) by a specific
GalNAc-T. It creates the oncofetal epitope required for FDC-6 binding (B). As
described, FDC-6 reacts exclusively with the O-glycosylated onfFN, but not
with non-O-glycosylated FN or plasma FN (pFN) (C).
cFN expressed by fibroblasts, but not with pFN. Furthermore, the
authors demonstrated that FNs isolated from normal adult tissues
were not reactive with FDC-6, whereas FNs isolated from estab-
lished cell lines, such as fetal and cancer tissues carried an extra
structure, which favored FDC-6 binding. This FN became known
as onfFN. Proteolytic digestion of glycoproteins showed that the
structure defined by FDC-6 antibody was present in the variable
(V) region or IIICS domain of FN (68). After characterization of
the primary structure of V region, Matsuura and colleagues iso-
lated the specific structure for FDC-6 binding. The comparison
of this structure with other structures that lack reactivity with
FDC-6 showed that the FDC-6 binding epitope was composed of
a GalNAc linked to Thr in the hexapeptide VTHPGY. In addi-
tion, the authors demonstrated that the reactivity is dependent
on the combination of both the sugar moiety and the peptide
unit, since neither the sugar nor the peptide moiety alone could
form the epitope structure (80). Further studies showed that the
FDC-6 non-reactive synthetic peptide containing the VTHPGY
sequence can be converted into FDC-6-reactive form. This hap-
pens after the incubation with GalNac-T and UDP-[3H]GalNAc
in the homogenate of carcinoma cell lines and the human fetal
fibroblast cell lines. Such a conversion did not take place when the
same enzyme fraction of normal adult tissue was incubated with
the VTHPGY peptide under the same conditions. Thus, the occur-
rence of GalNAc-T recognizing the VTHPGY peptide sequence
was shown to be specific for fetal and cancer tissues, and absent in
normal adult tissues (81).
It is now known that FN isoforms are developmentally reg-
ulated and generated as a result of alternative splicing of the
primary FN transcript (82). The mature FN molecules comprise
of a series of repeating amino acid sequences, termed as F-I, F-
II, and F-III structural modules. Twelve F-I modules make up
the amino-terminal and carboxy-terminal region of the mole-
cule, and are involved mainly in fibrin and collagen binding.
Only two F-II modules are found in FN. They are instrumental
in binding collagen. The most abundant module in FN is F-
III, which contains the RGD FN receptor recognition sequence
along with binding sites for other integrins and ECM components
(Figure 2A) (71). Depending on the tissue type and/or cellular
conditions, the FN molecule is made up of 15-17 F-III modules.
The V region, which does not fall into any of these categories,
along with extra domain B (EDB) and extra domain A (EDA)
(both F-III modules), is regulated through alternative splicing of
FN pre-mRNA (71). The V region is located between F-I and F-
III modules and can generate five (V0, V64, V89, V95, and V120)
different variants after the alternative splicing (71, 72). All vari-
ants, except V0 may contain the hexapeptide (VTHPGY) that
can be O-glycosylated on its Thr residue by a specific GalNAc-
T, creating the oncofetal epitope required for the FDC-6 binding
(Figure 2B).
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As described above, FDC-6 reacts exclusively with O-
glycosylated onfFN, but not with non-O-glycosylated FN or
plasma FN (pFN) (Figure 2C). onfFN has been identified within
several human tumors and developmental tissues (83–85). Fur-
thermore, a few recent reports have demonstrated that both
O-glycosylated and non-O-glycosylated FNs display distinct func-
tionalities in cancer cells undergoing EMT (see section below)
(86–88). However, further studies are necessary to clarify their
divergent roles in cancer evolution.
Although the development of a cancer cell arises from epige-
netic alterations, as well as somatic mutations in essential genes
for cell physiology, the selective pressures that take place in the
tumor microenvironment are crucial for the emergence of trans-
formed cells with different genotypes and/or glycophenotypes.
These events can modulate signaling pathways that exert control
on proliferation, motility, and half-life, which create conditions
for such cells to acquire invasive properties. For a long time, little
was known about the biology of cancer cells with metastatic prop-
erties. However, with the advent of experimental models, which
allowed the studies of molecular pathways triggered in invasive
cancer cells has generated valuable information that can be used
for future diagnostic and therapeutic purposes.
THE ROLE OF EMT IN CANCER PROGRESSION AND
METASTASIS
Given the ultimate diversity of tissues in a mature organism, cells
can adopt different fates. This process, known as differentiation,
provides cells with their distinct identities and specialized func-
tions. Initially, it was thought that differentiation was a one-way
process, and those terminally differentiated cells, i.e., cells of the
epithelium, were unable to lose their individuality and differentiate
toward a cell type of another lineage. However, more recent studies
have shown that cells of the epithelium can dedifferentiate toward
a mesenchymal state, enabling the cells to migrate, and form new
structures at a distant site. This phenomenon termed EMT is a
crucial biological event that takes place during embryonic develop-
ment and wound healing. Next to these physiological events, EMT
pathways are also activated during diseases. Cancer cells can go
through EMT to detach from the primary tumor, migrate toward
the vasculature, get transported by the blood circulation through
the body, and settle at a distant site where metastatic foci can be
formed (89–92). Nowadays, all hallmarks of EMT can be moni-
tored in vitro, and this unique experimental model has been used to
shed light on the molecular, biochemical, and biomechanical cues
of invasive cells. In literature, three different subtypes of EMT
are recognized. Although EMT, by definition, results in the for-
mation of migratory mesenchymal cells, each subtype represents
a specific biological event (93). The earliest EMT (type 1 EMT)
is highly regulated and is associated with embryonic implantation
and organ formation. Type 2 EMT is associated with inflammation
and fibrosis, and is now increasingly recognized in adult patholog-
ical conditions. In the context of fibrosis, the inflammation persists
and fibroblastic cells accumulate in the tissue, secreting large con-
centrations of ECM components. The deposition of these ECM
components inhibits organ function and can ultimately lead to
organ failure and organ destruction (94). Type 3 EMT is asso-
ciated with cancer progression and occurs in epithelial tumors
FIGURE 3 |The epithelial–mesenchymal transition. EMT is a
morphogenetic process in which epithelial cells lose their characteristics
and gain mesenchymal properties during embryogenesis and during
progression of cancer. Carcinoma cells acquire a mesenchymal-like state in
order to facilitate their migration and invasion. The EMT process is induced
and regulated by effectors such as growth factors (TGFβ), as well by
hypoxia. It is characterized by loss of epithelial markers (E-cadherin,
cytokeratins, occludin, and ZO-1), gain of mesenchymal markers
(N-cadherin, vimentin, and fibronectin) and high expression of MMPs,
which help cancer cells grow and spread.
(95, 96). Figure 3 illustrates how the type 3 EMT may modulate
the cancer cell progression.
In normal epithelial tissues, the cells are shown tightly juxta-
posed and form a polarized sheet with differing apical and basal
surfaces. When the genes involved in the control of cell growth and
cell death undergo epigenetic alterations and somatic mutations,
the mutated cells proliferate in an uncontrolled way, and favor the
development of carcinoma in situ (Figure 3). Growth factors, such
as TGF-β, and the compromised oxygen demand (hypoxia con-
dition) in the tumor microenvironment activates the molecular
pathways related to EMT. During this process, EMT master regula-
tors, such as the transcription factors Twist, Snail, and SIP1, lead to
dramatic changes in gene expression profiles and cellular behavior.
Twist, Snail, and SIP1 repress E-cadherin expression via E-boxes
in its promoter and trigger expression of an entire EMT transcrip-
tional program. The cells show a spindle-like-shape, as well a sig-
nificant reduction of epithelial markers (E-cadherin, cytokeratins,
occludin, and ZO-1), which is accompanied by the emergence of
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mesenchymal markers (N-cadherin, vimentin, and FN). In addi-
tion, the transformed cells secrete metalloproteinases (MMPs),
which help degrade the basal membrane components and also
expresses high levels of mesenchymal integrins, which may facil-
itate their interaction with ECM components, such as collagen
fibers (Figure 3). Finally, the transformed cells are able to reach
the bloodstream and colonize distant organs and tissues induc-
ing metastasis (Figure 3). Over 45 years, it is well-accepted that
atypical glycosylation may be detected in all types of experimental
and human cancers. However, although many tumor-associated
antigens have been used as tumor glycobiomarkers, their role on
cancer evolution is not well studied. In part, this can be explained
by the difficulties in closely following the biochemical and molec-
ular events of tumor development and progression in vivo. Along
this line, the EMT process has helped us to unveil the cues of the
altered glycosylation in invasive cancer cells.
EMT: THE GLYCAN CONNECTION
There is universal agreement that most of the early events in the
emergence of neoplasia involve genetic alterations, and it seems
unlikely that altered glycosylation per se plays a major role at this
stage. However, few reports have demonstrated how these atypi-
cal glycosylations may govern the molecular pathways related to
cancer cell invasion and metastasis. The impact of altered gly-
cans modulating cancer cell behavior is of central significance in
recent cancer research. However, little attention has been given to
this topic, mainly because the structural and functional concepts
of glycosylation in cancer are more complex than those for cer-
tain proteins and their genes in defining cancer cell phenotypes.
Pioneering papers published by Hakomori’s group demonstrated
that the EMT process may be used to shed light on the impact
of atypical glycans expressed by invasive epithelial cells (86, 87,
97–99). After the first paper published in 2009, where the partici-
pation of specific glycosphingolipids (GSLs) in human and mouse
mammary epithelial cells undergoing EMT was demonstrated, a
few papers discussing the impact of atypical glycans, as well as the
altered expression of glyco-genes have been published (100–103).
However, the implication of the unusualO-linked glycans on EMT
process has not been well explored. So far, the impact of altered O-
glycans on EMT has been addressed to the O-glycosylated onfFN.
Although onfFN was discovered almost 30 years ago (68), until
very recently, there had been no studies that describe its role in
cancer biology. Over the last few years, the O-glycosylated onfFN
has only been used for diagnostic purposes (104).
Recent studies brought to light the involvement of onfFN
during the EMT process. The first report demonstrated the up-
regulation of onfFN in human prostate epithelial cells treated with
TGF-β. The authors observed that the treated cells expressed high
levels of mRNA for FN carrying the IIICS domain, which contains
the VTHPGY sequence (86). Although it is recognized that the
incubation of the hexapeptide cited above with the microsomal
fraction of cancer cells favored the appearance of the oncofe-
tal epitope, the identity of the GalNAc-T responsible for this
phenomenon remained unknown for a long time. Previous bio-
chemical studies revealed that both GalNAc-T3 and/or GalNAc-
T6 recombinant enzymes were able to glycosylate the VTHPGY
sequence, suggesting that one or both glycosyltransferases would
participate in onfFN biosynthesis (50). To analyze the relevance of
GalNAc-T3 and/or GalNAc-T6 on EMT, Freire-de-Lima and col-
leagues (86) silenced the expression of both glycosyltransferases
and observed that the double knockdown cells failed to undergo
TGF-β-induced EMT. These were the first results that evinced a
cell system where both GalNAc-T3 and GalNAc-T6 were involved
in onfFN biosynthesis, as well as indirectly demonstrating the
importance of O-glycosylated onfFN in human epithelial cells
undergoing EMT. To check the main type of FN expressed dur-
ing the EMT process, a new hybridoma, YKH1, which produces a
mAb directed against the non-O-glycosylated VTHPGY sequence
found in FNs expressed by normal tissues (norFN) has been pro-
duced (87). The comparative results revealed that TGF-β-treated
cells expressed a significant amount of onfFN when compared
with non-treated cells. On the other hand, there was no observable
change on YKH1 binding between the control and TGF-β treated
cells, suggesting that the majority, if not all of the FN produced
during EMT is onfFN (87). Additionally, both norFN and onfFN
were purified by immunoaffinity columns to directly evaluate their
relevance on EMT. Interestingly, the authors observed that only the
O-glycosylated onfFN was able to induce the EMT-related events
(87). Although the major ligands for onfFN, as well as the mole-
cular mechanisms triggered by this unusual glycoprotein are still
unknown, the results described above have a significant biological
impact, suggesting that onfFN may be further used as a possible
candidate for the development of vaccines with anti-carcinogenic
properties.
Increasing evidence suggests that a metabolic disturbance, such
as hyperglycemia, is closely linked to cancer development and
progression. Several epidemiological studies have confirmed that
diabetic patients are more susceptible to cancer development when
compared with healthy individuals (105–108). Furthermore, dia-
betic patients have a poorer prognosis than those non-diabetic
patients with the same types of cancer (109, 110). The exact
mechanism for the increased cancer risk in patients with dia-
betes is unknown. Due to a potential correlation between diabetes
and cancer, studies evaluating the cancer risk of medications
used to treat diabetes are emerging (111, 112). However, given
the importance of glycoconjugates on cell biology, the possibil-
ity that atypical glycans in diabetic individuals may support the
tumor development and/or evolution cannot be excluded. The up-
regulation of glucose transporters (Gluts), which contributes to
increased influx of glucose, is one of the metabolic facets adopted
by cancer cells. It is believed that ~95% of glucose is deviated to
the glycolytic pathway, and ~3–5% is skewed to the hexosamine
biosynthetic pathway (HBP) that generates the activated monosac-
charides UDP-GlcNac and UDP-GalNAc, which are essential for
the biosynthesis of N - and O-linked glycans respectively. Follow-
ing this thought process; it would not be surprising if cancer cells
maintained in a high glucose condition were able to express more
O-glycosylated onfFN than those cells kept in a normoglycemic
condition.
Over the last few years, several papers evinced that the mainte-
nance of different cell types in high glucose condition promoted
the up-regulation of FN expression (113, 114). Furthermore,
recent works have demonstrated that a high glucose condition con-
tributes to the increased production of TGF-β in vitro by diverse
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cell lines (115–117). It is well described that FN is an important
mesenchymal marker, and that TGF-β is a potently known EMT
inducer. However, no studies have shown a direct link between a
hyperglycemic condition and the EMT process. Furthermore, it is
not known what type of FN would be expressed in a hyperglycemic
condition. We recently demonstrated that the maintenance of a
human adenocarcinoma cell line (A549) in hyperglycemic, but not
in normoglycemic condition, was able to induce the EMT process,
which was accompanied by the up-regulation of the mRNA for
FN transcripts carrying the IIICS domain and onfFN expression
(88). In addition, we have shown that these phenomena seem to
be fully dependent of the endogenous TGF-β produced in high
glucose, since the neutralization of TGF-β by anti-TGF-β antibod-
ies abrogated the onfFN expression. These results have important
implications, since they make a direct link between diabetes, a
metabolic disorder which affects millions of people worldwide,
and carcinogenesis. It also reinforces the idea that aberrant glyco-
sylation of glycoconjugates in diabetic patients may have a key role
in oncogenesis and tumor progression. Further studies are going
on in our lab to clarify this hypothesis.
CONCLUSION
This review has summarized how unusual O-glycans may influ-
ence cancer cell behavior, focusing on the effects mediated by the
O-glycosylated onfFN in EMT, a biological phenomenon that has
revolutionized the study of carcinogenesis. As commented above,
several papers have described altered O-glycophenotypes adopted
by cancer cells. However, there are few reports regarding how these
alterations may govern the molecular pathways related to the can-
cer evolution. The involvement of atypical glycans in cancer cells
undergoing EMT is a topic still not well studied, but the area
is very promising, given the relevance of glycoconjugates in the
maintenance of cell homeostasis, as well by the fact that EMT pre-
cedes cell metastasis. Research efforts over the last few years have
concentrated on the impact of an unusual O-linked glycan in the
FN structure. Future results will be necessary to support previous
observations, but it is plausible to speculate that onfFN may be fur-
ther used as a promising candidate for an anti-cancer vaccine. Basic
Local Alignment Search Tool (BLAST) analysis (118) revealed that
human kallikrein 12 (h-klk12), a serine protease expressed by adult
and fetal tissues (119), share the sameVTHPGY sequence that isO-
glycosylated in the IIICS domain of human onfFN. It has been well
described that h-klk12 modulates many physiological processes
(120, 121), as well tumor cell invasion and metastasis (122, 123).
Previous studies have shown that cancer cells express kallikreins
with atypical glycophenotypes (124). Knowing this, it is reason-
able to speculate that h-klk12 may act as substrate for GalNAc-T3
and/or GalNAc-T6 to create the oncofetal epitope recognized by
FDC-6. However, this has never been demonstrated. In addition
to FN, other glycoproteins associated with cell adhesion, such as
cytokeratins (125, 126), plakoglobin (127, 128), E-cadherin (129),
and beta-catenin (63, 130) are known to express their peculiar O-
glycophenotypes. Although the EMT process is deeply associated
with glycosylation changes, there is little information regarding
the impact of the atypical O-linked glycans adopted by these gly-
coproteins in cancer cells undergoing EMT. Given the importance
of these O-glycophenotypes in the maintenance of epithelial cell
polarity, it would be interesting to further explore this topic in
cancer biology. Besides reinforcing the idea that oncoglycobiol-
ogy is an important biological field, one of the major goals of this
review is to show that the EMT model may render useful infor-
mation about the glycosylation changes in invasive and metastatic
cancer cells, which may be additionally used for therapeutic and
diagnostic purposes.
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